It is worth noting that the development of clinically applicable selective and effective inhibitors of FTO and other m6A regulatory proteins may provide new and more effective treatment strategies to treat cancer, especially when used in combination with emerging immunotherapies. This evidence concerns the gene FTO and cancer.